玉米须多糖对糖尿病小鼠肝损伤及糖代谢的影响
|
摘要
目的探讨玉米须多糖对糖尿病小鼠模型的护肝降糖作用及其对肝糖代谢的影响。方法将50只小鼠分为空白对照组(NC组)、高血糖对照组(HG组)、二甲双胍组(MET组)、25 mg/kg玉米须多糖组(SMP25组)及50 mg/kg玉米须多糖组(SM P50组),每组10只。采用腹腔注射四氧嘧啶方法制备糖尿病小鼠模型,利用血糖测试仪测定小鼠空腹血糖(FPG)浓度,通过比色法测定小鼠肝糖原含量,通过药物性肝损伤病理组织学评分系统(DILI-PSS)评估肝损伤情况。结果与HG组相比,SMP50组小鼠的FPG降低34.3%(P<0.001)、肝糖原含量提高321.5%(P<0.001);与MET组相比,SMP25、SMP50组小鼠肝糖元含量均升高(P<0.001),且肝细胞水肿和脂肪性变均减轻(P<0.001);SMP50组的降糖护肝作用优于SMP25组(P<0.001)。结论玉米须多糖可降低糖尿病小鼠的FPG,促进肝糖元的合成,并可减轻造模药物及高血糖引起的肝损害,有望成为糖尿病患者护肝降糖辅助治疗选择。
Objective To investigate the effects of stigma maydis polysaccharides on glycometabolism and liver protection in diabetic mice. Methods Fifty mice were divided into normal control group(NC group),hyperglycemia control group(HG group),metformin group(M ET group),25 mg/kg polysaccharide derived from stigma maydis group(SMP25 group),and 50 mg/kg polysaccharide derived from stigma maydis group(SMP50 group),ten in each group.The diabetic mice models were prepared by peritoneal injection of alloxan,the fasting plasma glucose(FPG) were measured by a blood glucose tester,the content of liver glycogen in mice were measured by colorimetry,and the liver injury was evaluated by drug-induced liver injury-pathological scroring system(DILI-PSS). Results Compared withHG group,FPG value was reduced by 34.3%(P<0.001),the content of glycogen was increased by 321.5% in SM P50 group; compared with M ET group,the contents of glycogen were increased(P<0.001),and hepatocyte edema and hepatic steatosis were reduced(P<0.001) in SM P25 and SM P50 groups; the effects of blood sugar control and liver protection in SM P50 group is better than those in SM P25 group(P < 0. 001). Conclusion Polysaccharides derived from stigma maydis can significantly reduce the FPG concentration,promote the synthesis of glycogen,reduce the liver injury caused by modeling drugs and hyperglycemia in diabetic mice,and is expected to provide a effective adjuvant treatment option for diabetics.
Objective To investigate the effects of stigma maydis polysaccharides on glycometabolism and liver protection in diabetic mice. Methods Fifty mice were divided into normal control group(NC group),hyperglycemia control group(HG group),metformin group(M ET group),25 mg/kg polysaccharide derived from stigma maydis group(SMP25 group),and 50 mg/kg polysaccharide derived from stigma maydis group(SMP50 group),ten in each group.The diabetic mice models were prepared by peritoneal injection of alloxan,the fasting plasma glucose(FPG) were measured by a blood glucose tester,the content of liver glycogen in mice were measured by colorimetry,and the liver injury was evaluated by drug-induced liver injury-pathological scroring system(DILI-PSS). Results Compared withHG group,FPG value was reduced by 34.3%(P<0.001),the content of glycogen was increased by 321.5% in SM P50 group; compared with M ET group,the contents of glycogen were increased(P<0.001),and hepatocyte edema and hepatic steatosis were reduced(P<0.001) in SM P25 and SM P50 groups; the effects of blood sugar control and liver protection in SM P50 group is better than those in SM P25 group(P < 0. 001). Conclusion Polysaccharides derived from stigma maydis can significantly reduce the FPG concentration,promote the synthesis of glycogen,reduce the liver injury caused by modeling drugs and hyperglycemia in diabetic mice,and is expected to provide a effective adjuvant treatment option for diabetics.
引文
[1]Lagani V,Koumakis L,Chiarugi F,et al.A systematic review of predictive risk models for diabetes complications based on large scale clinical studies[J].J Diabetes Complications,2013,27(4):407-413.
[2]Pyram R,Kansara A,Banerji MA,et al.Chronic kidney disease and diabetes[J].M aturitas,2012,71(2):94-103.
[3]Forbes JM,Cooper ME.Mechanisms of diabetic complications[J].Physiol Rev,2013,93(1):137-188.
[4]Hazlehurst JM,Woods C,Marjot T,et al.Non-alcoholic fatty liver disease and diabetes[J].M etabolism,2016,65(8):1096-1108.
[5]Ahmadieh H,Azar ST.Liver disease and diabetes:association,pathophysiology,and management[J].Diabetes Res Clin Pract,2014,104(1):53-62.
[6]Targher G,Byrne CD.Clinical review:nonalcoholic fatty liver disease:a novel cardiometabolic risk factor for type2 diabetes and its complications[J].J Clin Endocrinol M etab,2013,98(2):483-495.
[7]宋烨,王明彦,宋成武,等.玉米须水煎液对1型、2型糖尿病小鼠降血糖活性的研究[J].时珍国医国药,2013,24(11):2627-2630.SONG Ye,WANG M ingyan,SONG Chengw u,et al.Hypoglycemic effect of corn silk decoction in alloxan-induced type 1 and type 2 diabetic mice[J].Lishizhen M edicine and M ateria M edica Research,2013,24(11):2627-2630.
[8]朱亮,石海春,罗强,等.玉米须多糖的提取、组成和生物活性研究[J].四川大学学报(自然科学版),2013,50(3):631-637.ZHU Liang,SHI Haichun,LUO Qiang,et al.Purification,composition and biological activity of the polysaccharide isolated from corn silk[J].Journal of Sichuan University(Natural Science Edition),2013,50(3):631-637.
[9]陈琛,徐华影.玉米须抗糖尿病活性成分的分离及其作用机制研究[J].中成药,2015,37(7):1492-1497.CHEN Chen,XU Huaying.Separation of anti-diabetic constituents from corn stigma and their mechanism of action[J].Chinese Traditional Patent M edicine,2015,37(7):1492-1497.
[10]徐丹鸿,林道鹏.超声波法提取酸浆宿萼多糖条件的优化[J].保鲜与加工,2015,15(4):43-46.XU Danhong,LIN Daopeng.Optimization of ultrasonic extraction of polysaccharides in persistent calyx of physalis alkekengi[J].Storage and Process,2015,15(4):43-46.
[11]骆静方,魏巍,乔楠,等.鞣花酸对四氧嘧啶糖尿病小鼠的影响[J].中国糖尿病杂志,2016,24(7):649-651.LUO Jingfang,WEI Wei,QIAO Nan,et al.Effect of ellagic acid on alloxan-induced diabetes in mice[J].Chin J Diabetes,2016,24(7):649-651.
[12]Garcia-Cortes M,Lucena MI,Pachkoria K,et al.Evaluation of naranjo adverse drug reactions probability scale in causality assessment of druginduced liver injury[J].Aliment Pharmacol Ther,2008,27(9):780-789.
[13]Penckofer S,Doyle T,Byrn M,et al.State of the science:depression and type 2 diabetes[J].West J Nurs Res,2014,36(9):1158-1182.
[14]Waterfalli M,Musekiwa A,Engel ME,et al.The prevalence of type 2 diabetes mellitus among older people inAfrica:a systematic review study protocol[J].BM J Open,2014,4(6):e004747.doi:10.1136/bmjopen-2013-004747.
[15][No authors listed]Summary of revisions:standards of medical care in diabetes-2018[J].Diabetes Care,2018,41(Suppl 1):S4-S6.
[16]Chang CC,Yuan W,Roan HY,et al.The ethyl acetate fraction of corn silk exhibits dual antioxidant and antiglycation activities and protects insulin-secreting cells from glucotoxicity[J].BM C Complement Altern M ed,2016,16(1):432.
[17]Yang J,Li X,Xue Y,et al.Anti-hepatoma activity and mechanism of corn silk polysaccharides in H22 tumorbearing mice[J].Int J Biol M acromol,2014,64:276-280.
[18]宫春宇,郑喜群,陈泽峰,等.玉米须多糖现状研究[J].江苏农业科学,2016,44(3):4-7.GONG Chunyu,ZHENG Xiqun,CHEN Zefeng,et al.Research progress on polysaccharides from corn silk[J].The Jiangsu Agricultural Sciences,2016,44(3):4-7.
[19]Cha JH,Kim SR,Kang HJ,et al.Corn silk extract improves cholesterol metabolism in C57BL/6J mice fed high-fat diets[J].Nutr Res Pract,2016,10(5):501-506.
[20]Joel Z,Per-Henrik G.Strategies for diabetes management:using new er oral combination therapies early in the disease[J].Diabetes Ther,2016,7(4):621-639.
[21]Li W,Yuan G,Pan Y,et al.Network pharmacology studies on the bioactive compounds and action mechanisms of natural products for the treatment of diabetes mellitus:a review[J].Front Pharmacol,2017,2(8):1-9.
[22]Suzuki A,Brunt EM,Kleiner DE,et al.The use of liver biopsyevanluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology,2011,54(3):931-939.
[23]Ahn JM,Palk YH,Kim SH,et al.Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography w ith diabetes mellitus in patients w ith chronic liver disease[J].J Korean M ed Sci,2014,29(8):1113-1119.
[24]Kramer CK,Retnakaran R.Liver enzymes and type 2 diabetes:a complex tw o-w at relationship[J].J Diabetes Complications,2013,27(4):301-302.
[25]Garcia-Compean D,Gonzalez-Gonzalez JA,LavalleGonzalez FJ,et al.The treatment of diabetes mellitus of patients w ith chronic liver disease[J].Ann Hepatol,2015,14(6):780-788.
[2]Pyram R,Kansara A,Banerji MA,et al.Chronic kidney disease and diabetes[J].M aturitas,2012,71(2):94-103.
[3]Forbes JM,Cooper ME.Mechanisms of diabetic complications[J].Physiol Rev,2013,93(1):137-188.
[4]Hazlehurst JM,Woods C,Marjot T,et al.Non-alcoholic fatty liver disease and diabetes[J].M etabolism,2016,65(8):1096-1108.
[5]Ahmadieh H,Azar ST.Liver disease and diabetes:association,pathophysiology,and management[J].Diabetes Res Clin Pract,2014,104(1):53-62.
[6]Targher G,Byrne CD.Clinical review:nonalcoholic fatty liver disease:a novel cardiometabolic risk factor for type2 diabetes and its complications[J].J Clin Endocrinol M etab,2013,98(2):483-495.
[7]宋烨,王明彦,宋成武,等.玉米须水煎液对1型、2型糖尿病小鼠降血糖活性的研究[J].时珍国医国药,2013,24(11):2627-2630.SONG Ye,WANG M ingyan,SONG Chengw u,et al.Hypoglycemic effect of corn silk decoction in alloxan-induced type 1 and type 2 diabetic mice[J].Lishizhen M edicine and M ateria M edica Research,2013,24(11):2627-2630.
[8]朱亮,石海春,罗强,等.玉米须多糖的提取、组成和生物活性研究[J].四川大学学报(自然科学版),2013,50(3):631-637.ZHU Liang,SHI Haichun,LUO Qiang,et al.Purification,composition and biological activity of the polysaccharide isolated from corn silk[J].Journal of Sichuan University(Natural Science Edition),2013,50(3):631-637.
[9]陈琛,徐华影.玉米须抗糖尿病活性成分的分离及其作用机制研究[J].中成药,2015,37(7):1492-1497.CHEN Chen,XU Huaying.Separation of anti-diabetic constituents from corn stigma and their mechanism of action[J].Chinese Traditional Patent M edicine,2015,37(7):1492-1497.
[10]徐丹鸿,林道鹏.超声波法提取酸浆宿萼多糖条件的优化[J].保鲜与加工,2015,15(4):43-46.XU Danhong,LIN Daopeng.Optimization of ultrasonic extraction of polysaccharides in persistent calyx of physalis alkekengi[J].Storage and Process,2015,15(4):43-46.
[11]骆静方,魏巍,乔楠,等.鞣花酸对四氧嘧啶糖尿病小鼠的影响[J].中国糖尿病杂志,2016,24(7):649-651.LUO Jingfang,WEI Wei,QIAO Nan,et al.Effect of ellagic acid on alloxan-induced diabetes in mice[J].Chin J Diabetes,2016,24(7):649-651.
[12]Garcia-Cortes M,Lucena MI,Pachkoria K,et al.Evaluation of naranjo adverse drug reactions probability scale in causality assessment of druginduced liver injury[J].Aliment Pharmacol Ther,2008,27(9):780-789.
[13]Penckofer S,Doyle T,Byrn M,et al.State of the science:depression and type 2 diabetes[J].West J Nurs Res,2014,36(9):1158-1182.
[14]Waterfalli M,Musekiwa A,Engel ME,et al.The prevalence of type 2 diabetes mellitus among older people inAfrica:a systematic review study protocol[J].BM J Open,2014,4(6):e004747.doi:10.1136/bmjopen-2013-004747.
[15][No authors listed]Summary of revisions:standards of medical care in diabetes-2018[J].Diabetes Care,2018,41(Suppl 1):S4-S6.
[16]Chang CC,Yuan W,Roan HY,et al.The ethyl acetate fraction of corn silk exhibits dual antioxidant and antiglycation activities and protects insulin-secreting cells from glucotoxicity[J].BM C Complement Altern M ed,2016,16(1):432.
[17]Yang J,Li X,Xue Y,et al.Anti-hepatoma activity and mechanism of corn silk polysaccharides in H22 tumorbearing mice[J].Int J Biol M acromol,2014,64:276-280.
[18]宫春宇,郑喜群,陈泽峰,等.玉米须多糖现状研究[J].江苏农业科学,2016,44(3):4-7.GONG Chunyu,ZHENG Xiqun,CHEN Zefeng,et al.Research progress on polysaccharides from corn silk[J].The Jiangsu Agricultural Sciences,2016,44(3):4-7.
[19]Cha JH,Kim SR,Kang HJ,et al.Corn silk extract improves cholesterol metabolism in C57BL/6J mice fed high-fat diets[J].Nutr Res Pract,2016,10(5):501-506.
[20]Joel Z,Per-Henrik G.Strategies for diabetes management:using new er oral combination therapies early in the disease[J].Diabetes Ther,2016,7(4):621-639.
[21]Li W,Yuan G,Pan Y,et al.Network pharmacology studies on the bioactive compounds and action mechanisms of natural products for the treatment of diabetes mellitus:a review[J].Front Pharmacol,2017,2(8):1-9.
[22]Suzuki A,Brunt EM,Kleiner DE,et al.The use of liver biopsyevanluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology,2011,54(3):931-939.
[23]Ahn JM,Palk YH,Kim SH,et al.Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography w ith diabetes mellitus in patients w ith chronic liver disease[J].J Korean M ed Sci,2014,29(8):1113-1119.
[24]Kramer CK,Retnakaran R.Liver enzymes and type 2 diabetes:a complex tw o-w at relationship[J].J Diabetes Complications,2013,27(4):301-302.
[25]Garcia-Compean D,Gonzalez-Gonzalez JA,LavalleGonzalez FJ,et al.The treatment of diabetes mellitus of patients w ith chronic liver disease[J].Ann Hepatol,2015,14(6):780-788.